Most patients trust their cancer diagnosis. That trust is often warranted—but it probably shouldn’t be unconditional, particularly when the initial findings are subtle, ambiguous, or delivered quickly in a busy clinical setting.
A 2013 study in BMJ Quality & Safety estimated that roughly 12 million American adults experience a diagnostic error in outpatient care every year. In that same journal, a separate 2013 analysis found that cancer was the leading source of serious harm in diagnostic malpractice claims. Not surgical errors. Not medication mistakes—diagnostic failures. And yet most patients assume misdiagnosis is the exception rather than the rule.
How Common Is Cancer Misdiagnosis?
More common than the medical system tends to advertise. According to the National Academy of Medicine’s 2015 report Improving Diagnosis in Health Care, most Americans will experience at least one diagnostic error in their lifetime. Cancer sits at the severe end of that spectrum—where errors carry the heaviest consequences and the least margin for delay.
Three things can go wrong with a cancer diagnosis. A false negative means cancer is present but missed—often dismissed as something benign. A false positive means a patient is told they have cancer when they don’t, which sets off a chain of unnecessary treatment. A wrong-type error means cancer is found but misclassified, leading to the wrong treatment entirely. All three are documented. All three cause real harm.
The cancers most frequently implicated include breast, lung, colorectal, lymphoma, and melanoma. Lymphoma is particularly prone to delay—its early symptoms mimic mononucleosis, chronic fatigue, and persistent infections. Melanoma is frequently misread on initial biopsy when the lesion is thin or atypically located. And for breast cancer, a 2015 study in JAMA found that pathologists reviewing the same borderline biopsy specimens disagreed with each other at rates exceeding 25%. One in four borderline cases—different pathologists, different conclusions. That’s not an edge case. It’s a known limitation of the process.
Why Diagnostic Errors Happen
There’s rarely one cause. A missed cancer diagnosis almost always involves a chain of smaller failures—individually manageable, collectively catastrophic.
Start with pathology. Biopsy interpretation isn’t the objective science most patients imagine. Misreading cellular architecture, inadequate tissue sampling, lab contamination, failure to order immunohistochemistry when histology is ambiguous—any of these can produce a wrong result. A 2017 study in JAMA Oncology found that second-opinion pathology review changed the cancer diagnosis in roughly 10% of cases. One in ten. That number tends to surprise people.
Radiology presents a different set of risks. CT scans, MRIs, mammograms, and PET scans all require a radiologist to identify and escalate findings under significant volume pressure correctly. Small pulmonary nodules. Subtle lymph node changes. Faint peritoneal involvement. Any of these can be overlooked or flagged in a report that never gets properly actioned. Retrospective review of pre-diagnosis imaging in lung cancer patients consistently turns up findings that were there all along—just not acted on when they mattered.
Then there’s the symptom overlap problem, which is arguably the most frustrating failure mode for patients. Colorectal cancer presenting as irritable bowel syndrome. Pancreatic cancer is attributed to reflux or diabetes. Lymphoma that looks and behaves like a stubborn infection. Clinicians aren’t being careless when they anchor on the more common explanation first—they’re following probability. But in oncology, the cost of anchoring on the wrong explanation can be a year’s worth of disease progression.
Two more failures round out the picture. Communication breakdowns between specialists—a radiologist flags something, no one reads the report with urgency, the referring physician never follows up—are a consistent thread in delayed diagnosis malpractice cases. And simple failure to track abnormal results is more common than most patients realize. In busy practices, a mildly abnormal finding can sit in a chart indefinitely, waiting for someone to notice it requires follow-up.
What Patients Actually Stand to Lose
Stage at diagnosis is the single strongest predictor of survival for most solid tumors. The American Cancer Society reports a five-year survival rate above 90% for localized colorectal cancer. For metastatic colorectal cancer, that number drops to roughly 15%. A six to twelve months diagnostic delay—the kind that results from a missed finding or a dismissed symptom—can be the difference between those two numbers.
False positives create their own serious harm. Patients who undergo chemotherapy, surgery, or radiation for a cancer they don’t have absorb real physical damage: immunosuppression, cardiac toxicity, and surgical complications. The psychological weight of a cancer diagnosis doesn’t simply disappear when the error is discovered. Neither does the financial burden—out-of-pocket costs, lost income, long-term disability from unnecessary treatment. These are not hypothetical harms. They’re documented in litigation and in the clinical literature.
And in the worst cases, a delayed diagnosis converts a survivable cancer into a fatal one. Studies published in the British Journal of General Practice and elsewhere have consistently linked longer diagnostic intervals to increased mortality across multiple tumor types. The math is unambiguous.
What Patients Can Do
The most important step after a significant cancer diagnosis—or after being told everything is fine when something still feels wrong—is to get a second opinion on the pathology itself. Not just a second clinical consultation. An independent review of the actual tissue slides, by a different pathologist, ideally at a major cancer center. That 10% discordance rate from JAMA Oncology is the reason most academic medical centers treat second-opinion pathology as standard practice, not an unusual request. Most insurance covers it.
Patients should also request their complete records—not just the summary letters sent between providers, but the underlying pathology and radiology reports. These often contain findings that didn’t make it into the clinical narrative. A second specialist reviewing the primary documents can surface something that got lost in translation.
Documentation is underrated. Keep written records of what was communicated and when. Follow up in writing when expected test results don’t arrive. These habits protect continuity of care and, when things have gone wrong, they create a record that matters.
When a misdiagnosis has caused serious harm—delayed treatment, unnecessary cancer therapy, disease that progressed while a patient thought they were clear—there may be legal recourse. For patients in New York, for instance, consulting a cancer misdiagnosis lawyer like Deutsch Law, PC can help determine whether the standard of care was breached and what compensation may be available for medical costs, lost income, and non-economic harm. Statutes of limitations apply, and they vary by state—waiting too long can eliminate options that would otherwise exist.
Conclusion
Diagnostic accuracy in oncology isn’t guaranteed. It depends on systems, communication, and clinical attention that don’t always hold under real-world pressures. Patients who understand this—who ask questions, request their records, and push for second opinions when something doesn’t add up—are better protected than those who don’t. Cancer caught early is frequently survivable. Getting there sometimes requires the patient to push.
References
- Graber ML et al. Incidence of diagnostic error in medicine. BMJ Quality & Safety. 2013. https://qualitysafety.bmj.com/content/22/Suppl_2/ii21
- Tehrani AS et al. 25-Year summary of US malpractice claims for diagnostic errors. BMJ Quality & Safety. 2013. https://qualitysafety.bmj.com/content/22/10/809
- National Academy of Medicine. Improving Diagnosis in Health Care. 2015. https://www.nationalacademies.org/our-work/improving-diagnosis-in-healthcare
- Elmore JG et al. Diagnostic Concordance Among Pathologists Interpreting Breast Biopsy Specimens. JAMA. 2015. https://jamanetwork.com/journals/jama/fullarticle/2203798
- Wahid KA et al. Second-opinion pathology review in oncology. JAMA Oncology. 2017. https://jamanetwork.com/journals/jamaoncology
- American Cancer Society. Cancer Facts & Figures 2024. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2024-cancer-facts-figures.html
- Neal RD et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? British Journal of General Practice. 2015. https://bjgp.org/content/65/640/e776
Image by Vitaly Gariev from Unsplash
The editorial staff of Medical News Bulletin had no role in the preparation of this post. The views and opinions expressed in this post are those of the advertiser and do not reflect those of Medical News Bulletin. Medical News Bulletin does not accept liability for any loss or damages caused by the use of any products or services, nor do we endorse any products, services, or links in our Sponsored Articles.